Latest News
-
Friday - October 23, 2020
Not intended for U.S. and UK Media
FDA approves FoundationOne®CDx as companion diagnostic for Vitrakvi™ (larotrectinib) to aid in identifying NTRK fusion-positive patients
The companion diagnostic (CDx) approval is part of the global collaboration between Bayer and Foundation Medicine, Inc. for the development and commercialization of next-generation sequencing (NGS)-based companion diagnostics in oncology / Detection of genomic alterations that drive the growth and spread of the tumor can guide treatment decisions for cancer therapies, such as available biomarker driven therapies / FoundationOne®CDx analyzes substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes as well as select rearrangements and genomic signatures across all solid tumors, including the three NTRK gene fusions (NTRK1, NTRK2 and NTRK3), to inform treatment decisions(1) / Vitrakvi™ (larotrectinib) is the first and only TRK-specific inhibitor approved in the U.S. for adult and pediatric patients with TRK fusion cancer across all solid tumors and is under review in other markets around the world » more
-
Friday - October 23, 2020
Not intended for U.S. and UK Media – Data from Phase III FIDELIO-DKD study presented at the American Society of Nephrology (ASN)’s Kidney Week 2020
Finerenone significantly reduced renal and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes
Finerenone is a first-in-class investigational non-steroidal, selective mineralocorticoid receptor (MR) antagonist that demonstrated renal and cardiovascular benefits in patients with chronic kidney disease and type 2 diabetes / Finerenone specifically addresses MR overactivation, a key driver of disease progression / Despite guideline-directed therapies, patients with chronic kidney disease and type 2 diabetes remain at high risk of progression to kidney failure and cardiovascular events / Results from the FIDELIO-DKD study were simultaneously published in the New England Journal of Medicine » more
-
Thursday - October 15, 2020
Leaps by Bayer leads USD 17 million Series B financing in biotech company Azitra
Harnessing the human skin microbiome to develop cutting-edge solutions moving the paradigm from treatment to cure in dermatology / Investment to support advancement of Azitra’s technology platform for both clinical and consumer programs » more
-
Wednesday - October 14, 2020
Not intended for U.S. and UK Media
Combination of copanlisib and rituximab significantly prolonged progression-free survival of patients with relapsed indolent non-Hodgkin's Lymphoma
Phase III study CHRONOS-3 in patients with relapsed indolent non-Hodgkin's Lymphoma (iNHL) who have received one or more lines of prior treatment meets primary endpoint / Safety and tolerability observed in the trial were generally consistent with previously published data on the individual components of the combination and no new safety signals were identified / Copanlisib is already approved in the U.S. under accelerated approval based on overall response rate (ORR) of 104 adult patients with relapsed follicular lymphoma (FL) based on the Phase II CHRONOS-1 study » more
-
Tuesday - October 13, 2020
Bayer Future of Farming Dialogue focuses on importance of sustainability in agriculture
Bayer helping transform the food system through innovation in agriculture
Despite the challenges posed by Covid-19, Bayer confirms significant progress on its sustainability commitments / Highly innovative carbon initiatives are redefining the value of farming by rewarding farmers for generating carbon credits when adopting climate-smart practices / Game-changing launch of VITALA, the first global launch of a short stature maize hybrid in Mexico, to help farmers produce more while using less resources » more
-
Monday - October 12, 2020
Not intended for U.S. and UK Media - American Society of Nephrology (ASN)’s Kidney Week 2020 Reimagined:
Finerenone Phase III FIDELIO-DKD study in chronic kidney disease and type 2 diabetes to be presented as late-breaking clinical trial at ASN 2020
FIDELIO-DKD is the first large contemporary positive outcomes study in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) with a primary composite endpoint consisting exclusively of kidney-specific outcomes / Finerenone, a first-in-class investigational non-steroidal, selective mineralocorticoid receptor (MR) antagonist, demonstrated positive renal and cardiovascular outcomes in patients with CKD and T2D / Preclinical data on finerenone, as well as a range of poster presentations in cardiovascular and kidney diseases will be presented » more
-
Wednesday - September 30, 2020
Bayer to accelerate transformation to address challenging market environment and enable additional growth investments
Adjusted outlook for 2020 confirmed / 2021 sales expected at approximately 2020 levels despite significant headwinds from COVID-19 pandemic; 2021 core earnings per share expected to be slightly below 2020 levels at constant exchange rates / Lower than expected outlook in the agricultural market likely to lead to mid-to-high single-digit billion-euro non-cash impairment charges in the Crop Science business / Strengthening margin profile and funding of additional investments in innovation and growth through additional operational savings, targeted at more than 1.5 billion euros annually as of 2024 / Dividend policy to remain unchanged, payout ratio planned at lower end of 30-to-40 percent range of core earnings per share in the coming years » more
-
Monday - September 21, 2020
Initiative offers financial support for novel approaches and enabling technologies in crop research
Bayer opens application window for Grants4Ag » more
-
Thursday - September 17, 2020
ESMO Virtual Congress 2020:
New data reinforce strong clinical profile of Vitrakvi™ for patients of all ages with TRK Fusion Cancer including lung and thyroid tumors
78% overall response rate (ORR) and median progression-free survival (PFS) of more than 3 years (36.8 months) demonstrate extended benefit in updated data set of 175 adults and children / Majority of adverse events were grade 1 or 2; no new safety signals identified / Consistently high ORRs shown in lung and thyroid data subsets (71 and 75%, respectively) as well as long durability (estimated duration of response at 12 months of 88% and 95%, respectively) / Among patients from integrated dataset with brain metastases (n=14), ORR was 71%, and 57% in patients with lung cancer with brain metastases (n=7) » more
-
Tuesday - September 15, 2020
Bayer Launches Large-scale Pre-launch Trial of New Tomato Varieties with Resistance to Tomato Brown Rugose Fruit Virus (ToBRFV)
The trials, which begin late September in Mexico, will target two varieties of Roma tomatoes which show little or no symptoms of ToBRFV / Developing these varieties aligns with Bayer’s commitment to provide fruit and vegetable seeds from its Seminis and De Ruiter brands which help growers combat the challenges they face each season » more
-
Tuesday - September 15, 2020
Not intended for U.S. and UK Media
Bayer and Systems Oncology sign exclusive license agreement on innovative breast cancer treatment approach ERSO™ » more
-
Thursday - September 10, 2020
Bayer: Supervisory Board extends CEO Werner Baumann’s contract until the end of April 2024
Company also announces progress in Roundup™ settlements » more
-
Wednesday - September 9, 2020
Not intended for U.S. and UK Media
New England Journal of Medicine publishes final overall survival data for Nubeqa™ (darolutamide) showing treatment significantly extends life in men with non-metastatic prostate cancer
Men with non-metastatic castration-resistant prostate cancer (nmCRPC) receiving darolutamide plus androgen deprivation therapy (ADT) had a significant improvement in overall survival (OS) compared to placebo plus ADT (HR=0.69, 95% CI 0.53-0.88; p=0.003) / Darolutamide significantly improved all other secondary endpoints, including time to first initiation of cytotoxic chemotherapy and first symptomatic skeletal event (SSE) / The safety profile at final analysis remains consistent with the earlier analysis; overall, the rate of adverse events was comparable to ADT alone » more
-
Wednesday - September 9, 2020
Bayer collaborates with Recursion to strengthen digital drug discovery and advance new therapies for fibrotic diseases
Drug Discovery partnership and equity investment led by Leaps by Bayer in Series D financing round / Digitally-powered drug discovery to address fibrotic diseases with previously undiscovered mechanisms and to deliver novel therapies to patients faster » more
-
Wednesday - September 9, 2020
Not intended for U.S. and UK Media
Bayer completes acquisition of UK-based biotech company KaNDy Therapeutics Ltd. » more
-
Tuesday - September 8, 2020
Not intended for U.S. and UK Media
Bayer to showcase new data from evolving Oncology portfolio at ESMO Virtual Congress 2020
Long-term efficacy and safety results for larotrectinib (Vitrakvi™) from an integrated data set of adult and pediatric patients with TRK fusion cancer, as well as sub-analyses in advanced thyroid and lung cancer patients / Tolerability and treatment response data from the Phase III ARAMIS trial investigating darolutamide (Nubeqa™) in men with non-metastatic castration-resistant prostate cancer (nmCRPC) / Continued research to explore potential of marketed products, evaluating regorafenib (Stivarga™) and radium-223 dichloride (Xofigo™) in combination with immunotherapies » more
-
Friday - August 28, 2020
Not intended for U.S. and UK Media
Bayer submits vericiguat for marketing authorization in China for the treatment of chronic heart failure » more
-
Thursday - August 27, 2020
Bayer and Northpond Ventures lead USD 55 million Series A financing round for Triumvira Immunologics
Leaps by Bayer and Northpond Ventures co-lead the investment to support development of next-generation immuno oncology treatments / Triumvira’s T-cell therapies have transformative potential as a new type of cancer treatment that uses the immune system to fight cancer / Pipeline includes four therapeutic candidates for both autologous and allogeneic T-cell immuno therapies for treatment of liquid and solid tumors » more
-
Thursday - August 27, 2020
Not intended for U.S. and UK Media
Bayer receives approval for Xofigo® in China » more
-
Monday - August 24, 2020
Bayer and Informed Data Systems Inc. (One Drop) join forces to jointly develop digital health products across therapeutic areas
Deal value up to USD 98 million including increased equity stake and joint development of digital health platform / Collaboration reinforces Bayer’s commitment to developing integrated care solutions for patients » more
Copyright @ Bayer AG
Search
Publications
Newsletter
Events
Tuesday, November 3, 2020
Q3 2020 Quarterly Statement News Conference Call Investor Conference Call
Additional Press Events
Investor Relations Events
BayKomm Events
Download Center - Selection
Bayer TV